Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

Most recent public disclosures: AI-powered summaries of the latest corporate filings

25851
1
Bakkt Holdings, Inc. Bakkt Holdings Reports $349M Revenue Surge and $103.4M Net Loss for 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25852
1
AMERICAN REALTY INVESTORS INC American Realty Investors Reports $14.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25853
1
AlTi Global, Inc. AlTi Global Reports $174.3 Million Net Loss for 2024, Revenue Declines to $206.9 Million

Via official filing (AI summary) | over 1 year ago | 0 comments

25854
1
GYRE THERAPEUTICS, INC. Gyre Therapeutics Reports $17.9M Net Income for 2024, Improved Profitability Amid Revenue Decline

Via official filing (AI summary) | over 1 year ago | 0 comments

25855
1
AGENUS INC Agenus Inc. Reports $232.3 Million Net Loss for 2024, Decreased R&D Revenue

Via official filing (AI summary) | over 1 year ago | 0 comments

25856
1
Akoya Biosciences, Inc. Akoya Biosciences Reports $81.7M Revenue in 2024, Faces Net Loss of $55.4M

Via official filing (AI summary) | over 1 year ago | 0 comments

25857
1
OCULUS INC. Oculus Inc. Reports $327,360 Net Loss for Fiscal Year 2024, Seeks Additional Financing

Via official filing (AI summary) | over 1 year ago | 0 comments

25858
1
FIBROGEN INC Fibrogen Reports 37% Revenue Decline to $29.6 Million for 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25859
1
Sana Biotechnology, Inc. Sana Biotechnology Reports $266.76 Million Net Loss for 2024, Improved from Previous Year

Via official filing (AI summary) | over 1 year ago | 0 comments

25860
1
ATAI Life Sciences N.V. ATAI Life Sciences Reports $149.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25861
1
SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports $97.9 Million Net Loss and Decreased Revenues in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25862
1
Metagenomi, Inc. Metagenomi Reports $78.1 Million Net Loss for 2024, Highlights IPO and R&D Progress

Via official filing (AI summary) | over 1 year ago | 0 comments

25863
1
CBAK Energy Technology, Inc. CBAK Energy Technology Reports $176.6M Revenue and $9.6M Net Income for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25864
1
FVCBankcorp, Inc. FVCBankcorp Reports Significant Increase in Net Income to $15.1 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25865
1
Cannabist Co Holdings Inc. The Cannabist Company Reports $105.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25866
1
COGNITION THERAPEUTICS INC Cognition Therapeutics Reports $33.97 Million Net Loss for 2024, Concludes Phase 2 MAGNIFY Study

Via official filing (AI summary) | over 1 year ago | 0 comments

25867
1
MSC INCOME FUND, INC. MSC Income Fund Reports $56.5M Net Increase in Assets for 2024, NYSE Listing Planned

Via official filing (AI summary) | over 1 year ago | 0 comments

25868
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports $8M Net Income for 2024, Driven by Neffy Launch

Via official filing (AI summary) | over 1 year ago | 0 comments

25869
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports $35.1 Million Net Loss for 2024, Highlights AlmataBio Acquisition

Via official filing (AI summary) | over 1 year ago | 0 comments

25870
1
Invivyd, Inc. Invivyd Reports $169.9 Million Net Loss for 2024, Highlights PEMGARDA Sales

Via official filing (AI summary) | over 1 year ago | 0 comments

25871
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports $72.7 Million Net Loss for 2024, Highlights Collaboration Revenue Growth

Via official filing (AI summary) | over 1 year ago | 0 comments

25872
1
Neuraxis, INC Neuraxis Reports $8.2 Million Net Loss, Revenue Increases by 9.2% in Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25873
1
22nd Century Group, Inc. 22nd Century Group Reports 24.3% Revenue Decline, Focuses on Reduced Nicotine Products

Via official filing (AI summary) | over 1 year ago | 0 comments

25874
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $63.7 Million Net Loss and Nil Revenue for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

25875
1
UNITED STATES ANTIMONY CORP United States Antimony Corporation Reports 72% Revenue Growth to $14.9 Million in Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments